We tested the hypotheses that the global incidence of bladder cancer was increasing but its mortality was reducing and its incidence was positively correlated with country-specific socioeconomic development. We retrieved data on age-standardized incidence and mortality rates/100,000 from the GLOBOCAN database in 2012. Temporal patterns were examined for 39 countries from the Cancer Incidence in Five Continents volumes I-X and other national registries. We evaluated the correlation between the incidence/mortality rates and Human Development Index (HDI)/ logarithmic values of Gross Domestic Product per capita (GDP). The average annual percent change of the incidence and mortality rates in the most recent 10 years was examined by joinpoint regression analysis. The highest incidence rates were observed in Southern Europe, Western Europe and North America. The mortality rates were the highest in Western Asia and Northern Africa. 
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. In Europe, a total of 118,000 new cases and 52,000 deaths were estimated in the same year 2 . Its high prevalence, in conjunction with its vulnerability to multiple recurrences and progression despite local therapy 3 , leads to a substantial health service burden 4 . Leal and colleagues 4 recently estimated that bladder cancer cost €4.9 billion in the European Union in 2012. The majority (90%) of bladder cancer consists of urothelial carcinoma as the predominant histologic type in Western Europe and the United States, although squamous cell bladder cancer is more common in Africa where schistosomiasis infections were more prevalent 5 . Recent studies showed that North America and Western Europe reported particularly high incidence rates 6 , whilst Eastern Europe and Asian countries had the lowest rates.
The major risk factors for bladder cancer include tobacco smoking; industrial exposure to potential carcinogens such as aromatic amines and carbon black dust; long-term drinking of arsenic-contaminated or chlorinated water; and family history of concordant cancers 7, 8 . Many of these risk factors can be modified by lifestyle measures and environmental protective initiatives, implying a strong prospect for intervention. Previous studies that analyzed its global trends were based on figures in the 1990s to early 2000s, did not make direct comparisons between countries, or performed in selected regions [8] [9] [10] [11] . The Global Burden of Disease Study 12 does provide comparison of bladder cancer incidence and mortality over time, but the temporal incidence and mortality trends of this cancer at the global level should be examined by recognized databases. Examining the patterns and temporal . the relationship between bladder cancer incidence/mortality and the world development index, but the influence of gender was not taken into account 14 . These findings highlight the need for a worldwide, across-country analysis of the epidemiological data.
This study tested the a priori hypothesis that the global temporal trends in the incidence of bladder cancer increased and that in its mortality decreased with time. Also, we sought to test the hypothesis that its global incidence was positively correlated with country-specific socioeconomic development.
Methods

Source of Data.
To standardize the methodology across published literature, we adopted the same analysis plan as reported in our previous study on prostate cancer 15 , liver cancer 16 , pancreatic cancer 17 and that on colorectal cancer 18 . We retrieved the incidence and mortality figures for bladder cancer in 2012 from the GLOBOCAN database 1 . For all countries, data were matched with their Human Development Index (HDI) and Gross Domestic Product (GPD) per capita in the same year based on the United Nations Human Development Report 19 , which highlighted the progress on human development over the past quarter century by reporting different statistical indexes. HDI is a summary index of life expectancy, education period, and income per capita 19 . For incidence trends, we extracted data from the Cancer Incidence in Five Continents series Volumes I-X 20 , which provided high-quality incidence statistics of cancer documented by local registries worldwide. This study has been approved by the Survey and Behavioural Research Ethics Committee of the Chinese University of Hong Kong. As this study used routinely collected anonymised electronic data consent was not required. All methods were performed in accordance with the relevant guidelines and regulations, and there were no publication of identifying information.
To acquire incidence data for more recent years, we also utilized publicly available information from the European Union Registration (EUREG) 21 , National used the GLOBOCAN data to analyze the incidence and mortality patterns in 2012, which were plotted against the HDI and logarithmic values of GDP per capita of each country in the same year. For analysis of temporal trends of incidence/mortality across time, we used the data from CI5 supplemented by the national databases [21] [22] [23] [24] [25] ( Table 1 ). The incidence data were retrieved according to the International Classification of Diseases (ICD-10, C67, 67.9; ICD-9-CM 188).
For mortality data, we used the WHO mortality database 26 and the various national databases [21] [22] [23] , where the primary data source originated from death certificates. These data were categorized based on the ICD 9 th 188 up to 2014. Table 1 showed a more detailed description of the data sources and calendar years for the present analysis. We used age-standardized rate per 100,000 (ASR) using the world standard population 27 . More developed regions include Europe, Northern America, Australia/New Zealand and Japan, whilst less developed regions include Africa, Asia (excluding Japan), Latin America and the Caribbean, Melanesia, Micronesia and Polynesia Statistical Analysis. We used joinpoint regression analysis to study the incidence and mortality trends 28 . A series of joined straight lines was fit to the ASR trend 28 . We performed logarithmic transformation of the ASRs and computed the standard errors adopting binomial approximation. A maximum number of three joinpoints were used as analysis options, and we evaluated the average annual percent change (AAPC) and the respective 95% confidence intervals (C.I.) for data available in the most recent 10 years. The AAPC was computerized as a geometrically weighted average of the generated APCs by the joinpoint trend analysis software. Their weights were equivalent to the length of each segment within the specified time interval 29 . We extracted data for the incidence and mortality trends from the above sources. We selected the most recent 10 years as the timeframe for examining temporal trend changes, as this was commonly adopted in previous studies on global epidemiology of other cancers 15, 18, 30 . All AAPCs with their 95% C.I. lying above and below zero, respectively, were regarded as increasing and decreasing trends. AAPCs with 95% C.Is overlapping with zero were considered as stable trends 15, 18, 30 . We plotted the ASRs of incidence and mortality against the HDI and logarithmic values of GDP per capita, respectively, for each country. The HDI was defined as low ( ≤ 0.534), medium (0.534-0.710), high 19 . Linear regression analysis was applied and correlation coefficients were evaluated, as linear associations had the best goodness-of-fit. Also, we estimated the percent change in incidence and mortality by 2020 and 2030 when compared to the latest published figures based on the AAPC -a statistical technique employed by Bailey and colleagues in a recent article published in JAMA Surgery 31 . The predicted incidence/mortality rates were assumed to be a constant percentage of the rate of the previous joinpoint. All p values <0.05 were considered statistically significant.
Results
Incidence and mortality rates of bladder cancer in 2012. A total of 429,793 new cases of bladder cancer and 165,084 related deaths were reported in 2012 (Tables 2 and 3 ). The age-standardized rate of its incidence showed approximately ten-fold variation worldwide 1 . In men, the highest rates were found in Southern Europe (ASR = 21.8), Western Europe (ASR = 19.7), North America (ASR = 19.5) and Western Asia (ASR = 19.0), and the lowest were reported in Western (ASR = 2.1), Middle (ASR = 2.2) and Eastern Africa (ASR = 3.3). This geographical difference is similar for incidence rates in women. Overall, countries that were more developed had higher incidence than less developed regions in both genders. The incidence in men was substantially higher in countries with very high HDI (ASR = 16.7) than those with high (ASR = 10.8), medium (ASR = 4.7) and low HDI (ASR = 3.1), and similarly this trend was also observed for women (Supplementary Figure 1) .
The mortality rates varied by seven-fold in 2012, and were higher in more developed than less developed regions (ASR = 4.5 vs. 2.6 in men; 1.1 vs. 0.7 in women). The highest mortality rates in men were reported in Western Asia (ASR = 8.4), Northern Africa (ASR = 7.6), and Central and Eastern Europe (ASR = 6.1). The lowest estimated death rates were found in Central America (ASR = 1.2), Micronesia/Polynesia (ASR = 1.2), Western Africa (ASR = 1.5), and Middle Africa (ASR = 1.6). In women, Northern Europe was amongst one of the world regions with the highest mortality (ASR = 1.5), whilst South-Eastern and South-Central Asia (ASR = 0.5) were regions that reported the lowest mortality rates.
Correlation between incidence/mortality and socioeconomic development. Figures 1A,B and 2A Among women, seven countries had increases in incidence, 8 countries showed declining trends, and trends in 24 countries remained stable. The majority of incidence rise occurred in Europe, and New Zealand also reported a significant incidence decline (AAPC = −6.7, 95% C.I. −12.5, −0.5, p = 0.04) (Fig. 4) .
Mortality trend.
In men, the only countries that showed increasing mortality trends include Ecuador Tables 4 and 5 summarized the projected incidence and mortality of bladder cancer by all future years up to 2030. The estimated increase in incidence by 2030 was most marked in Germany (998%), France (191%), Bulgaria (129%), and Brazil (164%) among men. In women, Brazil (1,380%), Germany (1,375%), Bulgaria (372%) and France (371%) were projected to have the highest incidence growth. Most countries included in this study showed declining mortality rates, except the Philippines (283%) and Ecuador (104%) that showed increase rates in men. Among women, Iceland (374%), the Philippines (245%), Ecuador (143%) and Malta (111%) showed prominent rise in mortality rates.
Projection of incidence and mortality rates in 2020 and 2030.
Discussion
This study presented the most updated global epidemiological profiles of bladder cancer, and we described the incidence and mortality patterns and trends based on high quality data. Southern Europe, Western Europe, Northern America and Western Asia reported the highest incidence rates, whilst Western, Middle and Eastern Africa had the lowest rates. In men, the highest mortality rates were observed in Western Asia, Northern Africa, and Central and Eastern Europe. with lowest death rates found in Central America, Micronesia/Polynesia, Western Africa, and Middle Africa. In women, high mortality rates were observed in Northern Europe, whilst South-Eastern and South-Central Asia reported the lowest mortality rates. Incidence rates were positively correlated with human development levels and logarithmic values of GDP per capita with high coefficients of correlation between incidence/mortality and HDI was moderately strong (0.50-0.66). Incidence figures from 39 countries in the most recent 10 years reported that a total of 7 countries experienced increases in incidence rates in either gender -and six of them were European countries. Up to 19 and 6 out of 38 countries reported reduction in mortality trends in men and women, respectively, and the majority of them were in Europe. Bulgaria is the only country where males had significant increase in both incidence and mortality. On the contrary, male populations in Oceania (i.e. Australia and New Zealand) went in declines in both incidence and mortality. German men and women reported increases in incidence but decreases in mortality. A reduction in both incidence and mortality in both genders could only be observed in USA.
A recent study by Antoni et al. 32 has examined the most recent global incidence and mortality patterns and trends of bladder cancer. They also reported the highest incidence rates in Southern and Western Europe, North America as well as in some nations in Northern Africa and Western Asia. It was found that the incidence rates were diverging, with stabilizing or decreasing rates for men but increasing rates for women in many countries. Our study utilized an approach similar to their design by using similar data sources, but the timeframe used to compute the AAPC and the registries used to extract the data were different.
Several reasons could explain the higher incidence of bladder cancer in more developed countries, and their positive correlation with HDI. Firstly, in developed nations with more rapid development and higher productivity, the prevalence of risk factors for bladder cancer including smoking, obesity, alcohol drinking and red-meat consumption was higher 7, 8 -and these risk factors have been reported by the World Health Organization as alarmingly high across Europe 33 . Tobacco use in developing nations is growing and has now surpassed that of developed nations where prevalence of tobacco use has begun to decrease 34 . To control it, the WHO FCTC (Framework Convention on Tobacco Control) were adopted by 174 countries and currently covering around 90% of the population globally 35 . There has been substantial interest in measuring the impact of tobacco use on health outcomes at the population level since the 1950s 36 . However, there are substantial differences between various surveys and a lag in the impact of tobacco control on smoking-related incidence and mortality 37 . While limited data was available to evaluate how the tobacco control has influenced the incidence or mortality of bladder cancer. In 2012, the WHO published the "WHO global report: mortality attributable to tobacco", showing the relative risk (males: 3.0, females: 2.4) for bladder cancer death due to tobacco use was just second to lung cancer 38 . Therefore, we can predict that the policies of tobacco control will have a substantial impact on the incidence and mortality of bladder cancer. Another explanation for the higher incidence could be attributed to the more widespread practice of diagnostic tests in more resource-privileged countries, such as urine cytology, cystoscopy and CT scan for haematuria and other non-specific urinary symptoms presented by patients 39 . Yet another possible contributor includes higher rates of occupational and environmental exposures to carcinogenic agents, including the aromatic amines in the dye industry in the European Union 40 . Our findings that some countries outside Europe and North America reported markedly increased incidence trends warrant further studies to elucidate the underlying etiological mechanisms. The reduction in mortality trends in the recent decade could be explained by decreasing incidence or earlier diagnosis leading to stage migration to earlier stage disease, which could be treated by curative intervention. Another driver for the mortality decline could be due to improved endoscopic system for cystoscopic surveillance 41 , use of re-staging (second look) transurethral bladder resection 42 and also better intravesical therapy for non-muscle invasive cancer 43 . This study presented and analyzed the most up-to-date epidemiological data on bladder cancer, and quantified the geographical variations as well as trends in its incidence and mortality using data of high validity, completeness and comparability. We also used national mortality data that were based on WHO criteria of at least medium level quality in terms of coverage and completeness. The IARCs estimation methods have been further refined in more recent years to take into account the increasing availability and quality of the source data 1 . However, some limitations of this study should be discussed. Firstly, cancer registration in relatively less-developed nations could suffer from higher chance of under-reporting. Population based cancer registries that only cover parts of a country can have limited representativeness for the whole population. This is especially true for many population based cancer registries in low-and middle income countries that are mostly located in urban areas. On the contrary, in countries where estimates were based on a single cancer registry in more urbanized, resource privileged areas, the presented figures could be an overestimation if the countries consist of extensive rural populations. In addition, analysis of bladder cancer incidence is affected by the underlying data -some might include only invasive bladder cancer and others might include both invasive and non-invasive bladder cancer. Different cancer registries have different policies on how the cancer is reported, and this could change over time. Also, information regarding the tissue type of bladder cancer, such as urothelial cancer and squamous cell carcinoma, was lacking. Morover, despite our most inclusive approach to analyze the most recent data, the figures used are from 2012 at the latest and the temporal trends will need continuous updates. Last but not least, the change in coding practice of bladder cancer might influence the comparison of incidence/mortality trend of this disease across years. For instance, since 2000, the definition of bladder carcinoma was coded as invasive disease (ICD-10, C67), and it led to an apparent decrease in the incidence of bladder carcinoma as well as the survival rate due to the exclusion of carcinoma in situ that bears better prognosis. Although after years of efforts, the definition has become more universal across the cancer registries of different countries in recent years, there was a period around year 2000 with a mixed definition, which made the comparison of incidence/mortality rates among different registry systems difficult. Future analysis should be performed before and after this time period to capture the changes in trends more accurately.
Conclusion
The incidence rates of bladder cancer increased in many European countries analyzed in this study, and the mortality rates declined in a large number of nations, particularly in more developed regions. With population ageing and population growth, the absolute incidence of bladder cancer might be further escalating in European nations. Appropriate healthcare resources should be allocated to cope with the increasing need for patient treatment. Future studies are needed to explore the underlying mechanisms for these epidemiological trends with potential risk factors incorporated in further analysis.
